The laboratory response to glucagon dosages used in gastrointestinal examinations.

Chernish SM, Maglinte DD, Brunelle RL

Investigative radiology1 Nov 1988Cited by 6 (Europe PMC)

PMID3061974DOI10.1097/00004424-198811000-00009PepBankPUB-03061974

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients receiving glucagon, serum glucose increased linearly with intravenous or intramuscular doses up to 1 mg, then decreased slightly at 2 mg.
In plain wordsIn patients, blood glucose rose with increasing glucagon doses through 1 mg and fell slightly at 2 mg.
Peptide
Glucagon
Outcome
MixedSerum glucose dose response
Study
n: not reported in source
Comparator
Other tested glucagon doses
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.25-2 mg · intravenous or intramuscularAs given in this study (human).
Source sentences
Summary
When glucagon was given intravenously or intramuscularly in increasing doses, serum values for glucose and insulin increased linearly up to 1 mg with a slight decrease at 2 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197401
02HumanNon-randomized trialEfficacy outcome
In patients receiving glucagon, serum insulin increased linearly with intravenous or intramuscular doses up to 1 mg, then decreased slightly at 2 mg.
In plain wordsIn patients, blood insulin rose with increasing glucagon doses through 1 mg and fell slightly at 2 mg.
Peptide
Glucagon
Outcome
MixedSerum insulin dose response
Study
n: not reported in source
Comparator
Other tested glucagon doses
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
0.25-2 mg · intravenous or intramuscularAs given in this study (human).
Source sentences
Summary
When glucagon was given intravenously or intramuscularly in increasing doses, serum values for glucose and insulin increased linearly up to 1 mg with a slight decrease at 2 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197402
03HumanNon-randomized trialEfficacy outcome
In patients, white blood cell counts increased after intravenous and intramuscular glucagon.
In plain wordsIn patients, white blood cell counts rose after intravenous and intramuscular glucagon.
Peptide
Glucagon
Outcome
IncreaseWhite blood cell count
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25-2 mg · intravenous or intramuscularAs given in this study (human).
Source sentences
Summary
After intravenous and intramuscular administration of glucagon, the white blood cell count and the percentage of neutrophiles and bands increased, and the percentage of lymphocytes decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197403
04HumanNon-randomized trialEfficacy outcome
In patients, the percentage of neutrophiles increased after intravenous and intramuscular glucagon.
In plain wordsIn patients, the proportion of neutrophils rose after intravenous and intramuscular glucagon.
Peptide
Glucagon
Outcome
IncreaseNeutrophil percentage
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25-2 mg · intravenous or intramuscularAs given in this study (human).
Source sentences
Summary
After intravenous and intramuscular administration of glucagon, the white blood cell count and the percentage of neutrophiles and bands increased, and the percentage of lymphocytes decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197404
05HumanNon-randomized trialEfficacy outcome
In patients, the percentage of bands increased after intravenous and intramuscular glucagon.
In plain wordsIn patients, the proportion of immature neutrophils rose after intravenous and intramuscular glucagon.
Peptide
Glucagon
Outcome
IncreaseBand percentage
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25-2 mg · intravenous or intramuscularAs given in this study (human).
Source sentences
Summary
After intravenous and intramuscular administration of glucagon, the white blood cell count and the percentage of neutrophiles and bands increased, and the percentage of lymphocytes decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197405
06HumanNon-randomized trialEfficacy outcome
In patients, the percentage of lymphocytes decreased after intravenous and intramuscular glucagon.
In plain wordsIn patients, the proportion of lymphocytes fell after intravenous and intramuscular glucagon.
Peptide
Glucagon
Outcome
DecreaseLymphocyte percentage
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25-2 mg · intravenous or intramuscularAs given in this study (human).
Source sentences
Summary
After intravenous and intramuscular administration of glucagon, the white blood cell count and the percentage of neutrophiles and bands increased, and the percentage of lymphocytes decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197406
07HumanNon-randomized trialSafety outcome
In patients receiving intravenous glucagon, one report of nausea occurred.
In plain wordsOne report of nausea occurred in patients receiving intravenous glucagon.
Peptide
Glucagon
Outcome
Direction not reportedNausea after intravenous glucagon
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.25-2 mg · intravenousAs given in this study (human).
Measurements
Nausea reports
1 report
intravenous
Source sentences
Summary
Reports of side effects included one each of nausea and mouth dryness after intravenous glucagon and four reports of nausea and one of mouth dryness after intramuscular glucagon.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197407
08HumanNon-randomized trialSafety outcome
In patients receiving intravenous glucagon, one report of mouth dryness occurred.
In plain wordsOne report of dry mouth occurred in patients receiving intravenous glucagon.
Peptide
Glucagon
Outcome
Direction not reportedMouth dryness after intravenous glucagon
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.25-2 mg · intravenousAs given in this study (human).
Measurements
Mouth dryness reports
1 report
intravenous
Source sentences
Summary
Reports of side effects included one each of nausea and mouth dryness after intravenous glucagon and four reports of nausea and one of mouth dryness after intramuscular glucagon.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197408
09HumanNon-randomized trialSafety outcome
In patients receiving intramuscular glucagon, four reports of nausea occurred.
In plain wordsFour reports of nausea occurred in patients receiving intramuscular glucagon.
Peptide
Glucagon
Outcome
Direction not reportedNausea after intramuscular glucagon
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.25-2 mg · intramuscularAs given in this study (human).
Measurements
Nausea reports
4 reports
intramuscular
Source sentences
Summary
Reports of side effects included one each of nausea and mouth dryness after intravenous glucagon and four reports of nausea and one of mouth dryness after intramuscular glucagon.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197409
10HumanNon-randomized trialSafety outcome
In patients receiving intramuscular glucagon, one report of mouth dryness occurred.
In plain wordsOne report of dry mouth occurred in patients receiving intramuscular glucagon.
Peptide
Glucagon
Outcome
Direction not reportedMouth dryness after intramuscular glucagon
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.25-2 mg · intramuscularAs given in this study (human).
Measurements
Mouth dryness reports
1 report
intramuscular
Source sentences
Summary
Reports of side effects included one each of nausea and mouth dryness after intravenous glucagon and four reports of nausea and one of mouth dryness after intramuscular glucagon.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197410
11HumanNon-randomized trialSafety outcome
In patients, no pulse change could be attributed to glucagon administration.
In plain wordsIn patients, glucagon did not produce an attributable change in pulse.
Peptide
Glucagon
Outcome
No significant changePulse
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
0.25-2 mg · intravenous or intramuscularAs given in this study (human).
Source sentences
Summary
No changes in the pulse and blood pressure could be attributed to glucagon administration.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197411
12HumanNon-randomized trialSafety outcome
In patients, no blood pressure change could be attributed to glucagon administration.
In plain wordsIn patients, glucagon did not produce an attributable change in blood pressure.
Peptide
Glucagon
Outcome
No significant changeBlood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.25-2 mg · intravenous or intramuscularAs given in this study (human).
Source sentences
Summary
No changes in the pulse and blood pressure could be attributed to glucagon administration.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain the effects of glucagon on these patients, we determined the biochemical and hematologic responses to doses of 0.25-2 mg of glucagon in a double-blind crossover study.
Report a problemFND-0306197412

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.